A clinical trial to evaluate Bryostatin in the treatment of Fragile X syndrome
Latest Information Update: 12 Aug 2021
At a glance
- Drugs Bryostatin-1 (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- 12 Aug 2021 New trial record
- 05 Aug 2021 According to a Synaptogenix media release, the company has signed a memorandum of understanding (MOU) with the Nemours A.I. DuPont Hospital for Children, with the intention of initiating a trial to treat Fragile X with Bryostatin.